2021厄达替尼erdafitinib美国价格是多少？厄达替尼中国上市没有？

FGFR (fibroblast growth factor receptor) is a protein on cells that helps them grow and divide. Some bladder cancer patients have changes in genes that tell cells to produce FGFR, which can help cancer cells grow. Erdafitinib works by targeting cells with these genetic changes. Indications for: Locally advanced or metastatic urothelial carcinoma with predisposing FGFR3 or FGFR2 genetic alterations that have progressed during or after at least 1 prior line of platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Relevant clinical trial data show that the therapeutic effect of erdafitinib is significant. Has the drug been launched in China? What is the price of this drug in the United States?

What is the price of erdafitinib in the United States in 2021? Is erdafitinib available in China?

In the United States, erdafitinib is sold by Johnson & Johnson Pharmaceuticals, and the price is US$8,020 for 3mg*30 tablets. It is understood that Erdafitinib has not been officially launched in mainland China, so patients cannot purchase the drug in mainland China. Erdafitinib exported to Hong Kong by Janssen is 4mg*28 tablets with a price of about $106,500. Patients can look for domestic overseas medical service agencies (such as Medical Companion Travel) to purchase the medicines, which will be delivered to the patients by direct mail. They will also provide guidance and answer questions for the patients during the medication process. This is currently the most economical and feasible solution.

Related clinical trials of erdafitinib

Treatment with the oral FGFR inhibitor erdafitinib showed consistent efficacy in patients with locally advanced or metastatic urothelial cancer and FGFR gene mutations after a median follow-up of two years in the BLC2001 phase II clinical trial. The research is a breakthrough for patients with mutations in the FGFR3 gene, which is present in about 15 to 20 percent of patients with metastatic bladder cancer. For decades, the standard treatment for these cancers has been aggressive treatment with cisplatin-based chemotherapy, a very powerful drug with significant side effects. In recent years, new checkpoint blockade inhibitors have been approved, however, responses to these immunotherapies are only about 15% to 20%.

At a median follow-up of two years, the therapy resulted in a median overall survival of 11.3 months and an objective tumor response rate of 40%. Additionally, 12-month and 24-month survival rates were 49% and 31%, respectively, with 31% of patients responding for more than a year.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Related hot articles